Pharma: Clinic Roundup

• UCB SA, of Brussels, Belgium, reported post-hoc analyses of pivotal trials of Neupro (rotigotine transdermal system) in patients with restless legs syndrome (RLS)/Willis Ekbom disease, showing improvements with rotigotine vs. placebo in most of the single items from the International RLS Study Group Rating Scale scores, which measured sensory-motor dysfunction, severity of sleep disturbance and the impact of RLS on daily activities. Those and other findings were presented at the American Academy of Neurology meeting in New Orleans.